RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company’s strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel.
Related Questions
What is the expected timeline for commercial launch of the ART500 and its impact on near‑term revenue?
How does the newly approved patent strengthen Inspira's competitive position relative to other extracorporeal oxygenation providers?
What assumptions underlie the $20 billion market estimate and how realistic is capturing a meaningful share?